Positive clinical data supports BrainsWay's scientific narrative and could drive adoption among clinicians treating MDD with suicidal ideation. However, the lack of FDA clearance for this specific indication limits immediate commercial impact. Monitor for any future FDA submission or label expansion announcements. The 20-F (filed April 2026) showed strong revenue growth of 27% to $52.2M, providing fundamental support alongside this clinical catalyst.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Aug 27 $14.40entry
- T+1 · 3mo ago −0.69%α −0.47% · $14.30
- T+5 · 2mo ago +0.76%α +0.50% · $14.51
- T+20 · 7w ago −8.26%α −7.76% · $13.21
- T+56 · todayOpen
- T+60 · in 4d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BrainsWay announced publication of a peer-reviewed secondary analysis in the Journal of Affective Disorders showing a 70% relative reduction in suicidal ideation among MDD patients treated with Deep TMS (from 22.5% to 6.7% over 6 weeks). The data adds to a growing body of 2026 research supporting Deep TMS for suicidality, though the device is not FDA-cleared for this indication. The filing is a clinical-data update without financial figures, providing incremental positive evidence for label expansion potential.
Key Facts
- 70% relative reduction in patients with suicidal ideation (SSI>0) from 22.5% at baseline to 6.7% after 6 weeks of Deep TMS
- Median time to improvement in suicidality was 10 days with SWIFT accelerated protocol vs 13 days with standard protocol (statistically significant)
- Data published in Journal of Affective Disorders as secondary analysis of prior multisite randomized trial that supported FDA clearance of SWIFT in September 2025
- Deep TMS is not FDA-cleared for treatment or prevention of suicidal ideation or behavior
Financial Impact
No financial figures provided; potential label expansion catalyst for Deep TMS in MDD, which could expand addressable market if future FDA clearance obtained
Risk Factors
- Secondary analysis data, not a prospective randomized trial designed for suicidality endpoint
- Deep TMS not FDA-cleared for suicidal ideation, no near-term label expansion
- Small sample size (89 patients) limits statistical robustness
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-005759 |
| Document: 0001171843-26-005759-index-headers.html | 0001171843-26-005759 |
| Document: 0001171843-26-005759-index.html | 0001171843-26-005759 |
| Document: 0001171843-26-005759.txt | 0001171843-26-005759 |
Track record
24 reports on BWAY
6 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +27.55% at T+60 after the Mar 4, 2026 report. 7 of 10 went positive at some point.
Filters
- Nov 10, 20266d ago 6-K Bullish 6/10 No price data
- Nov 10, 20266d ago 6-K Neutral 5/10 Entry $10.67 Now $9.39 −12.00% settles Dec 9
- Nov 2, 202614d ago 6-K Neutral 3/10 Entry $11.09 Now $9.39 −15.33% settles Dec 1
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $11.09 Now $9.39 −15.33% settles Dec 1
- Oct 26, 202621d ago 6-K Neutral 3/10 Entry $11.21 Now $9.39 −16.24% settles Nov 23
- Oct 21, 202626d ago 6-K Neutral 3/10 Entry $11.44 Now $9.39 −17.92% settles Nov 19
- Oct 19, 202628d ago 6-K Neutral 3/10 Entry $11.99 Now $9.39 −21.68% due Nov 16
- Oct 19, 202628d ago Press Release Neutral 4/10 Entry $11.99 Now $9.39 −21.68% due Nov 16
- Oct 13, 20264w ago 6-K Neutral 4/10 Entry $11.92 to $10.67 Now $9.39 −21.22% ▼ −10.49% −6.88% vs SPY
- Sep 8, 20269w ago 6-K Neutral 4/10 Entry $14.16 to $11.89 Now $9.39 −33.69% ▼ −16.03% −18.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers